Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric surgery: a Retrospective Observational Study.

Jensen AB, Renström F, Aczél S, Folie P, Biraima-Steinemann M, Beuschlein F, Bilz S

Obesity surgery11 Feb 2023Cited by 126 (Europe PMC)

PMID36765019PMCIDPMC9918402DOI10.1007/s11695-023-06484-8PepBankPUB-36765019

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with weight regain after bariatric surgery, pooled GLP-1 receptor agonist treatment (liraglutide or semaglutide) reduced weight by 8.8% of total body weight after 6 months.
In plain wordsIn adults with weight regain after bariatric surgery, GLP-1 drugs as a group, including liraglutide, were followed by weight loss.
Peptide
Liraglutide
Outcome
DecreaseWeight loss after 6 months, pooled GLP-1 RA
Study
n = 50
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Weight reduction
8.8 % of total body weight
pooled GLP1-RA
Source sentences
Summary
After 6 months of GLP1-RA treatment, a reduction in weight and BMI of 8.8% (5.2, 11.4) of total body weight and 2.9 kg/m² (1.8, 4.0) was observed (P value <0.0001), corresponding to 67.4% (40.4, 92.2) of the weight regain.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with 6 months of treatment with GLP1-RA, up until November 2021, due to weight regain after bariatric surgery were identified.
Summary · context
Before GLP1-RA treatment (liraglutide, n=29; semaglutide, n=21), weight and BMI were 90.5 kg (83.4, 107.9) and 34.0 kg/m² (31.7, 38.7), respectively, with a post-bariatric weight regain of 15.1% (10.6, 22.8) of total body weight and 4.6 kg/m² (3.3, 6.2).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3676501901
02HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with weight regain after bariatric surgery, pooled GLP-1 receptor agonist treatment (liraglutide or semaglutide) reduced BMI by 2.9 kg/m2 after 6 months.
In plain wordsIn adults with weight regain after bariatric surgery, GLP-1 drugs as a group, including liraglutide, were followed by a lower BMI.
Peptide
Liraglutide
Outcome
DecreaseBMI reduction after 6 months, pooled GLP-1 RA
Study
n = 50
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
BMI reduction
2.9 kg/m2
pooled GLP1-RA
Source sentences
Summary
After 6 months of GLP1-RA treatment, a reduction in weight and BMI of 8.8% (5.2, 11.4) of total body weight and 2.9 kg/m² (1.8, 4.0) was observed (P value <0.0001), corresponding to 67.4% (40.4, 92.2) of the weight regain.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with 6 months of treatment with GLP1-RA, up until November 2021, due to weight regain after bariatric surgery were identified.
Summary · context
Before GLP1-RA treatment (liraglutide, n=29; semaglutide, n=21), weight and BMI were 90.5 kg (83.4, 107.9) and 34.0 kg/m² (31.7, 38.7), respectively, with a post-bariatric weight regain of 15.1% (10.6, 22.8) of total body weight and 4.6 kg/m² (3.3, 6.2).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3676501902
03HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
In adults with weight regain after bariatric surgery, pooled GLP-1 receptor agonist treatment (liraglutide or semaglutide) corresponded to loss of 67.4% of the weight regain.
In plain wordsAfter bariatric surgery with weight regain, GLP-1 drugs as a group, including liraglutide, were followed by loss of about two-thirds of the regained weight.
Peptide
Liraglutide
Outcome
DecreaseProportion of weight regain lost, pooled GLP-1 RA
Study
n = 50
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Weight regain lost
67.4%
pooled GLP1-RA
Source sentences
Summary
After 6 months of GLP1-RA treatment, a reduction in weight and BMI of 8.8% (5.2, 11.4) of total body weight and 2.9 kg/m² (1.8, 4.0) was observed (P value <0.0001), corresponding to 67.4% (40.4, 92.2) of the weight regain.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with 6 months of treatment with GLP1-RA, up until November 2021, due to weight regain after bariatric surgery were identified.
Summary · context
Before GLP1-RA treatment (liraglutide, n=29; semaglutide, n=21), weight and BMI were 90.5 kg (83.4, 107.9) and 34.0 kg/m² (31.7, 38.7), respectively, with a post-bariatric weight regain of 15.1% (10.6, 22.8) of total body weight and 4.6 kg/m² (3.3, 6.2).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3676501903
04HumanNot a test of Liraglutide aloneObservational studySafety outcome
In adults with weight regain after bariatric surgery, no serious adverse events were reported with pooled GLP-1 receptor agonist treatment (liraglutide or semaglutide).
In plain wordsIn adults with weight regain after bariatric surgery, no serious side effects were reported with GLP-1 drugs as a group, including liraglutide.
Peptide
Liraglutide
Outcome
No significant changeSerious adverse events, pooled GLP-1 RA
Study
n = 50
Outcome group
Adverse events · Whole body
Source sentences
Summary
No serious adverse events were reported.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with 6 months of treatment with GLP1-RA, up until November 2021, due to weight regain after bariatric surgery were identified.
Summary · context
Before GLP1-RA treatment (liraglutide, n=29; semaglutide, n=21), weight and BMI were 90.5 kg (83.4, 107.9) and 34.0 kg/m² (31.7, 38.7), respectively, with a post-bariatric weight regain of 15.1% (10.6, 22.8) of total body weight and 4.6 kg/m² (3.3, 6.2).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3676501904
05HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with weight regain after bariatric surgery, pooled GLP-1 receptor agonist treatment (liraglutide or semaglutide) reduced weight by 8.8% of total body weight after 6 months.
In plain wordsIn adults with weight regain after bariatric surgery, GLP-1 drugs as a group, including semaglutide, were followed by weight loss.
Peptide
Semaglutide
Outcome
DecreaseWeight loss after 6 months, pooled GLP-1 RA
Study
n = 50
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Weight reduction
8.8 % of total body weight
pooled GLP1-RA
Source sentences
Summary
After 6 months of GLP1-RA treatment, a reduction in weight and BMI of 8.8% (5.2, 11.4) of total body weight and 2.9 kg/m² (1.8, 4.0) was observed (P value <0.0001), corresponding to 67.4% (40.4, 92.2) of the weight regain.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with 6 months of treatment with GLP1-RA, up until November 2021, due to weight regain after bariatric surgery were identified.
Summary · context
Before GLP1-RA treatment (liraglutide, n=29; semaglutide, n=21), weight and BMI were 90.5 kg (83.4, 107.9) and 34.0 kg/m² (31.7, 38.7), respectively, with a post-bariatric weight regain of 15.1% (10.6, 22.8) of total body weight and 4.6 kg/m² (3.3, 6.2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3676501905
06HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with weight regain after bariatric surgery, pooled GLP-1 receptor agonist treatment (liraglutide or semaglutide) reduced BMI by 2.9 kg/m2 after 6 months.
In plain wordsIn adults with weight regain after bariatric surgery, GLP-1 drugs as a group, including semaglutide, were followed by a lower BMI.
Peptide
Semaglutide
Outcome
DecreaseBMI reduction after 6 months, pooled GLP-1 RA
Study
n = 50
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
BMI reduction
2.9 kg/m2
pooled GLP1-RA
Source sentences
Summary
After 6 months of GLP1-RA treatment, a reduction in weight and BMI of 8.8% (5.2, 11.4) of total body weight and 2.9 kg/m² (1.8, 4.0) was observed (P value <0.0001), corresponding to 67.4% (40.4, 92.2) of the weight regain.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with 6 months of treatment with GLP1-RA, up until November 2021, due to weight regain after bariatric surgery were identified.
Summary · context
Before GLP1-RA treatment (liraglutide, n=29; semaglutide, n=21), weight and BMI were 90.5 kg (83.4, 107.9) and 34.0 kg/m² (31.7, 38.7), respectively, with a post-bariatric weight regain of 15.1% (10.6, 22.8) of total body weight and 4.6 kg/m² (3.3, 6.2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3676501906
07HumanNot a test of Semaglutide aloneObservational studyEfficacy outcome
In adults with weight regain after bariatric surgery, pooled GLP-1 receptor agonist treatment (liraglutide or semaglutide) corresponded to loss of 67.4% of the weight regain.
In plain wordsAfter bariatric surgery with weight regain, GLP-1 drugs as a group, including semaglutide, were followed by loss of about two-thirds of the regained weight.
Peptide
Semaglutide
Outcome
DecreaseProportion of weight regain lost, pooled GLP-1 RA
Study
n = 50
Comparator
Baseline
Outcome group
Body weight · Metabolic and weight
Measurements
Weight regain lost
67.4%
pooled GLP1-RA
Source sentences
Summary
After 6 months of GLP1-RA treatment, a reduction in weight and BMI of 8.8% (5.2, 11.4) of total body weight and 2.9 kg/m² (1.8, 4.0) was observed (P value <0.0001), corresponding to 67.4% (40.4, 92.2) of the weight regain.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with 6 months of treatment with GLP1-RA, up until November 2021, due to weight regain after bariatric surgery were identified.
Summary · context
Before GLP1-RA treatment (liraglutide, n=29; semaglutide, n=21), weight and BMI were 90.5 kg (83.4, 107.9) and 34.0 kg/m² (31.7, 38.7), respectively, with a post-bariatric weight regain of 15.1% (10.6, 22.8) of total body weight and 4.6 kg/m² (3.3, 6.2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3676501907
08HumanNot a test of Semaglutide aloneObservational studySafety outcome
In adults with weight regain after bariatric surgery, no serious adverse events were reported with pooled GLP-1 receptor agonist treatment (liraglutide or semaglutide).
In plain wordsIn adults with weight regain after bariatric surgery, no serious side effects were reported with GLP-1 drugs as a group, including semaglutide.
Peptide
Semaglutide
Outcome
No significant changeSerious adverse events, pooled GLP-1 RA
Study
n = 50
Outcome group
Adverse events · Whole body
Source sentences
Summary
No serious adverse events were reported.
2 context sentences(design, population, supporting numbers)
Summary · context
Patients with 6 months of treatment with GLP1-RA, up until November 2021, due to weight regain after bariatric surgery were identified.
Summary · context
Before GLP1-RA treatment (liraglutide, n=29; semaglutide, n=21), weight and BMI were 90.5 kg (83.4, 107.9) and 34.0 kg/m² (31.7, 38.7), respectively, with a post-bariatric weight regain of 15.1% (10.6, 22.8) of total body weight and 4.6 kg/m² (3.3, 6.2).
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-3676501908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 4NCT06132477

Impact GLP-1 Agonists Following Bariatric

University of Missouri-Columbian = 1501 Feb 2024 to est. Jul 2030

Morbid Obesity · Metabolic Syndrome · Diabetes Mellitus · Hypertension · Obstructive Sleep Apnea of Adult

Trial page ClinicalTrials.govUpdated 21 Oct 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.